Rise in patient reporting boosts EU drug safety signals
This article was originally published in Scrip
The introduction of direct reporting of adverse drug reactions by patients in Europe appears to have had the desired effect: in 2013, the number of ADRs reported by patients within the European Economic Area (EEA) rose by more than 50% as a result of greater public awareness of the importance of such reporting.
You may also be interested in...
Health activists are stepping up the pressure on COVID-19 vaccine companies to share their IP and reveal their costs, while the European Medicines Agency has published regulatory guidance advising vaccine developers to aim for a point estimate of efficacy of at least 50%.
The EU has ambitious plans for dealing with future health crises, bolstering needs-led innovation, improving access to medicines, and tackling drug shortages.
In its latest communication to medical product companies, the DHSC says the biggest potential cause of disruption to supplies could be failure to prepare for border controls implemented by the EU member states after the end of the Brexit transition period.